Trial Profile
Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Reloxaliase (Primary)
- Indications Hyperoxaluria
- Focus Registrational; Therapeutic Use
- Acronyms URIROX-1
- Sponsors Allena Pharmaceuticals
- 04 Jan 2022 According to an Allena Pharmaceuticals media release, data from this study are expected to be published during the first half of 2022.
- 09 Mar 2021 According to an Allena Pharmaceuticals media release, patients will also continue to be followed for a minimum of two years to confirm clinical benefit, including the ability of reloxaliase to reduce the incidence and severity of kidney stone disease and renal impairment, to support potential accelerated approval.
- 13 May 2020 According to an Allena Pharmaceuticals media release, a late-breaking abstract detailing kidney stone risk and its association with urinary oxalate levels in patients with enteric hyperoxaluria was accepted for presentation as part of the American Urological Association (AUA) Virtual Education Experience, which is being held in place of the cancelled AUA 2020 Annual Meeting.